HAGAR N.I.G.

HAGAR N. I. G. is an Israeli company specializing in innovative non-invasive blood glucose monitoring solutions, utilizing advanced radio frequency technology to enhance diabetes management for users worldwide.

Founded in 2017 in Tel Aviv, Israel, HAGAR N. I. G. focuses on developing non-invasive glucometers.

The company has completed a total of 3 funding rounds, with the most recent Series C round raising USD 5. 00 mn on August 10, 2023. The funding has facilitated the growth and development of their core product offerings. GWave is at the forefront of non-invasive blood glucose monitoring technology, offering a groundbreaking device that utilizes radio frequency (RF) waves for continuous and real-time measurement of glucose levels in the blood.

The core product, developed by GWave's CTO Dr. Geri Waintraub, emerged from a serendipitous discovery during RF device experimentation. This technology not only eliminates the discomfort associated with traditional finger-prick tests but also provides a more accurate reading by monitoring glucose in the blood rather than interstitial fluid. The device features Bluetooth connectivity, allowing seamless integration with smartphones, and includes a user-friendly app for tracking glucose readings.

The target user base includes millions of individuals globally living with diabetes, with particular focus on markets in North America, Europe, and Asia, where there is a high demand for innovative diabetes management solutions. GWave generates revenue through direct sales of its flagship non-invasive glucometer, which is supported by a subscription-based model for its software and cloud services. The company has successfully secured funding rounds, which indicate strong investor confidence and facilitate continued research and development. Transactions typically occur directly with consumers, allowing users to purchase the device and subscribe to ongoing services that enhance their monitoring experience.

The product pricing structure reflects the advanced technology and features, providing affordable options for consumers while ensuring accessibility for a broad audience. As GWave continues to expand its reach, revenue opportunities may also include partnerships with medical professionals and healthcare facilities, enhancing the overall value proposition of its offering. In August 2023, HAGAR N. I.

G. raised USD 5. 00 mn in Series C funding from unspecified investors. The company plans to leverage this funding to enhance its product line and introduce new monitoring solutions within the next year.

Additionally, HAGAR N. I. G. aims to penetrate new markets, specifically targeting regions in North America, Europe, and Asia by 2024.

This strategic expansion is expected to increase accessibility and support for individuals managing diabetes globally.